Medical Device Alert: Abiomed Impella Purge Cassette Recall (Class I)
Abiomed has initiated a Class I recall, the most serious classification issued by the U.S. Food and Drug Administration, for certain Impella purge cassettes and associated pump sets due to a critical risk of purge system failure.
This recall involves the removal of affected devices from use and distribution, reflecting a high-risk failure mode that may result in serious injury or death if not addressed.
Affected Devices
The following products are included in the recall.
The Impella RP US Pump Set
Product Code: 004334
Serial Number: 434937A
UDI-DI: 00813502011029
Purge Cassette, 5 Pack (Generation 1)
Product Code: 0043-0003
UDI-DI: 00813502011135
Reason for Recall
Abiomed has identified an increased risk of purge cassette leaks in Generation 1 Purge Cassettes.
Device Function (Clinical Context)
The purge cassette is a critical component of the Impella system that delivers purge fluid to the catheter and prevents blood ingress into the microaxial pump motor as it maintains continuous device function during circulatory support.
The failure of the system directly compromises device reliability and patient safety.
Failure Mechanism
A purge cassette leak will lead to reduced purge pressure that can cause biomaterial ingress into the pump motor. That introduction of biomaterials will then cause an unexpected pump stop.
Clinical Impact
The clinical impact of the pump stopping is an immediate loss of hemodynamic support which will lead to the potential for rapid patient deterioration and a risk of patient death.
As of February 3, 2026, four serious injuries have been reported and no deaths were reported.
Required Actions for Healthcare Facilities
Immediate Actions
Identify and quarantine all Abiomed Impella Generation 1 purge cassettes, remove affected units from use, and initiate returns in accordance with Abiomed instructions.
Operational Guidance
Transition existing Impella devices to Generation 2 Purge Cassettes. If Generation 1 must be used, implement enhanced monitoring of purge system and respond immediately to a “Purge Pressure Low” alarm on Automated Impella Controller (AIC). Follow IFU instructions without deviation.
Communication and Control
Notify all relevant personnel (clinical, supply chain, biomedical) and inform any downstream facilities if product was redistributed. Post the recall notice in visible operational areas.
Manufacturer Contact Information
U.S. customers experiencing adverse events or requiring support should contact Abiomed by email at OneMD-Field-Actions@its.jnj.com.
Regulatory and Quality System Observations
This recall highlights several important QMSR / ISO 13485:2016 considerations.
Risk Management (ISO 13485 §7.1 / ISO 14971 integration)
Failure mode of a leak leading to a pump stop indicates a high-severity hazard chain and suggests potential gaps in design FMEA (DFMEA) and the verification of purge system integrity under real-world conditions.
Design & Development (ISO 13485 §7.3)
The transition from the Generation 1 to Generation 2 cassettes indicates a design corrective action and likely postmarket-driven design modification.
Postmarket Surveillance & CAPA (ISO 13485 §8.2 / §8.5)
Identification of field failures and injuries demonstrates an active complaint handling system that lead to a CAPA escalation and then a field action / recall.
Production & Process Controls (ISO 13485 §7.5)
Potential contributing factors may be material integrity issues, robustness of assembly processes, and a possible lack of leak-proof validation testing.
Advisory Notices (ISO 13485 §8.3.3)
This recall exemplifies proper execution of a Field Safety Corrective Action (FSCA) and product traceability via UDI-DI.
MDP Perspective
This event underscores a fundamental principle in life-sustaining device systems. Ancillary components (like purge cassettes) can represent single points of catastrophic failure. From a regulatory and quality standpoint, manufacturers should re-evaluate system-level risk interactions (not just component-level risks), strengthen alarm-response validation (human factors and system response time), ensure robust leak detection and prevention mechanisms, and incorporate real-world use conditions into design validation protocols.
Links
Read the FDA’s announcement here.
Pharmacal Recalls MG217 Eczema Cream
Pharmacal Recalls MG217 Eczema Cream Due to Staphylococcus aureus ContaminationFDA posts nationwide recall after microbial contamination found in topical skin treatment Pharmacal has voluntarily recalled one lot of MG217 Multi-Symptom Treatment Cream & Skin...
Cefazolin Injection Recalled Due to Cardboard in Sterile IV Solution
Baxter Recalls Cefazolin Injection Sterile IV SolutionCardboard Particulate Matter Found in a Sterile Intravenous Infusion Bag Baxter International has voluntarily recalled one lot of Cefazolin in Dextrose Injection, USP, 2 g/100 mL after a report of cardboard...
FDA Closes Moringa Salmonella Outbreak Investigation
The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention have concluded their investigation into a multistate Salmonella Typhimurium outbreak linked to MOGO-brand moringa powder capsules distributed by MOGO Moringa LLC of St. Louis,...
Why the Sudden Focus on Testosterone?
New Military Screening Program Raises Questions About Science, Strategy and TransparencyThe Trump administration's decision to begin annual testosterone screening for active-duty and reserve service members age 30 and older has generated headlines and a growing number...
Arrow Corrects Kits With Recalled Injectable Medications
FDA Classifies Field Correction As Class I Recall Due to Risk of Serious Injury The U.S. Food and Drug Administration (FDA) has classified a correction issued by Arrow International, a subsidiary of Teleflex, as a Class I recall after certain convenience kits were...
FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol
FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor for High CholesterolLipfendra offers patients a once-daily pill alternative to injectable PCSK9 therapies The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral medication...
